-
V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
J Virol. 2000 Aug;74(15):6769-76
PMID: 10888615
-
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
J Virol. 2006 Jul;80(14):7127-35
PMID: 16809318
-
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.
J Virol. 2001 Mar;75(5):2041-50
PMID: 11160708
-
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
J Virol. 2001 Apr;75(7):3435-43
PMID: 11238869
-
Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
J Virol. 2001 May;75(9):4208-18
PMID: 11287570
-
Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76
PMID: 11485624
-
Evolutionary and immunological implications of contemporary HIV-1 variation.
Br Med Bull. 2001;58:19-42
PMID: 11714622
-
Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia.
J Virol. 2002 Jan;76(1):397-405
PMID: 11739704
-
Diversity considerations in HIV-1 vaccine selection.
Science. 2002 Jun 28;296(5577):2354-60
PMID: 12089434
-
Antibody neutralization and escape by HIV-1.
Nature. 2003 Mar 20;422(6929):307-12
PMID: 12646921
-
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
J Virol. 2003 Jun;77(12):6965-78
PMID: 12768015
-
Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
J Virol. 2003 Jul;77(14):8061-71
PMID: 12829845
-
Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
J Virol. 2004 Jan;78(1):524-30
PMID: 14671134
-
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Virology. 2004 Mar 30;321(1):8-22
PMID: 15033560
-
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Science. 2004 Mar 26;303(5666):2019-22
PMID: 15044802
-
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
J Virol. 2004 May;78(10):5205-15
PMID: 15113902
-
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52
PMID: 1717992
-
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
J Virol. 1992 Feb;66(2):848-56
PMID: 1370558
-
Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
J Virol. 1993 Aug;67(8):4932-44
PMID: 7687306
-
Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
J Virol. 1994 Jan;68(1):400-10
PMID: 7504740
-
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
J Virol. 1994 Apr;68(4):2253-9
PMID: 8139010
-
Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
J Clin Invest. 1994 Jun;93(6):2505-13
PMID: 7515393
-
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
J Virol. 1994 Jul;68(7):4636-42
PMID: 7515975
-
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
J Virol. 1994 Dec;68(12):8312-20
PMID: 7525987
-
Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
Arch Virol. 1994;139(3-4):253-61
PMID: 7832633
-
Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.
Virology. 1995 Feb 1;206(2):878-84
PMID: 7856100
-
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
J Virol. 1995 Apr;69(4):2271-8
PMID: 7533854
-
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
J Virol. 1995 Sep;69(9):5723-33
PMID: 7543586
-
Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.
J Virol. 1996 Feb;70(2):1310-6
PMID: 8551601
-
Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
J Virol. 1997 Oct;71(10):7719-27
PMID: 9311856
-
The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1291-9
PMID: 9339846
-
Rapid HIV testing and counseling for voluntary testing centers in Africa.
AIDS. 1997 Sep;11 Suppl 1:S103-10
PMID: 9376093
-
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59
PMID: 9641677
-
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
J Virol. 1998 Oct;72(10):7840-5
PMID: 9733820
-
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
J Virol. 1998 Oct;72(10):8437-45
PMID: 9733899
-
Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
J Virol. 1999 Jul;73(7):5294-300
PMID: 10364275
-
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
J Virol. 2004 Dec;78(23):13232-52
PMID: 15542675
-
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
J Virol. 2005 Jan;79(2):780-90
PMID: 15613306
-
Structure of an unliganded simian immunodeficiency virus gp120 core.
Nature. 2005 Feb 24;433(7028):834-41
PMID: 15729334
-
Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.
J Virol. 2005 Apr;79(8):4828-37
PMID: 15795268
-
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.
J Virol. 2005 Apr;79(8):5232-7
PMID: 15795308
-
Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
J Virol. 2005 May;79(10):6528-31
PMID: 15858037
-
The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
J Virol. 2005 Jun;79(11):6909-17
PMID: 15890930
-
The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
J Virol. 2005 Jul;79(14):9069-80
PMID: 15994801
-
Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.
Retrovirology. 2005;2:67
PMID: 16274482
-
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
J Virol. 2006 Jan;80(2):750-8
PMID: 16378977
-
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.
J Virol. 2006 Jan;80(2):835-44
PMID: 16378985
-
Global epidemiology of HIV.
J Med Virol. 2006;78 Suppl 1:S7-S12
PMID: 16622870
-
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.
J Virol. 2006 Jun;80(11):5211-8
PMID: 16699001